Telephone sharing button Contact Us mailbox sharing button
arrow_left sharing button
arrow_right sharing button

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 Total number of integrated projects increased to 143 50 new integrated projects signed in 2023...

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan 31, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for...

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?